Italian Multicentric Prospective Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib

Trial Profile

Italian Multicentric Prospective Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms INNOVATE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
    • 03 Jun 2016 New Trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top